People · Operator
Named in public records as an officer, director or promoter · active 2010–2019 · Other Technology, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| TWELVE, Inc. | — | Other Technology | Series B | $88.8M | $1.1B | 2010 |
| Ocular Therapeutix, Inc | — | Biotechnology | Series B | $81.0M | $1.5B | 2019 |
Charles A. Warden at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Charles A. Warden on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| FARHAD KHOSRAVI | 1 | 14 |
| Richard Lindstrom | 1 | 13 |
| Hanson S. Gifford III | 1 | 11 |
| Alan Crane | 1 | 9 |
| Amarpreet Sawhney | 1 | 8 |
| Brian Levy | 1 | 8 |
| Richard L Lindstrom | 1 | 8 |
| Henry A. Plain, Jr. | 1 | 7 |
| James Garvey | 1 | 6 |
| Henry A. Plain | 1 | 5 |
| Charles Warden | 1 | 5 |
| Steven Cagnetta | 1 | 5 |
| Mark Deem | 1 | 5 |
| Christopher A. Shen | 1 | 3 |
| Hanson Gifford | 1 | 3 |
| Nimesh A. Shah | 1 | 2 |
| Mark S. Deem | 1 | 2 |
| Samuel Wu | 1 | 2 |
| Daniel Myers | 1 | 2 |
| Jaswinder Chadha | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.